Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS), Pacific Biosciences (PACB) and Humana (HUM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioLife Solutions (BLFS – Research Report), Pacific Biosciences (PACB – Research Report) and Humana (HUM – Research Report).

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

BioLife Solutions (BLFS)

KeyBanc analyst Paul Knight maintained a Buy rating on BioLife Solutions today and set a price target of $33.00. The company’s shares closed last Thursday at $25.91.

According to TipRanks.com, Knight is a 3-star analyst with an average return of 2.3% and a 41.2% success rate. Knight covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Lifecore Biomedical, and Standard BioTools. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $31.14 average price target, a 19.6% upside from current levels. In a report issued on October 1, Craig-Hallum also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

Pacific Biosciences (PACB)

In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences, with a price target of $1.50. The company’s shares closed last Thursday at $1.43, close to its 52-week low of $1.11.

According to TipRanks.com, Sergott ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.4% and a 35.6% success rate. Sergott covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Fortrea Holdings Inc., and Charles River Labs. ;'>

Pacific Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.08, representing a 48.6% upside. In a report issued on September 19, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.50 price target.

Humana (HUM)

Barclays analyst Andrew Mok CFA maintained a Hold rating on Humana today and set a price target of $245.00. The company’s shares closed last Thursday at $256.62.

According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.5% and a 50.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'>

Humana has an analyst consensus of Moderate Buy, with a price target consensus of $297.16, which is a 20.7% upside from current levels. In a report issued on September 22, Evercore ISI also initiated coverage with a Hold rating on the stock with a $295.00 price target.

Read More on BLFS:

Disclaimer & DisclosureReport an Issue

• BioLife Solutions management to meet virtually with KeyBanc
• BioLife Solutions Holds Annual Stockholders Meeting
• BioLife Solutions Reports Strong Q2 Growth Amid Challenges
• BioLife Solutions: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
• BioLife Solutions price target raised to $32 from $30 at H.C. Wainwright